Glucagon: A Technical Pros and Cons Analysis
Title: Glucagon: A Technical Pros and Cons Analysis Abstract: Glucagon, a 29-amino-acid peptide hormone, is critical for glucose homeostasis. Its primary therapeutic advantage lies in rapid severe hypoglycemia reversal, with a 100% bioavailability via intramuscular injection. However, technical drawbacks include short half-life ( 6 min) requiring reconstitution before use, and instability in liquid form. Market trends show a shift toward stable glucagon analogs (e.g., dasiglucagon) and nasal powder formulations (Baqsimi), improving patient compliance. Key brand comparisons highlight Lilly’s Glucagon vs. Xeris’s Gvoke (ready-to-use liquid). Industry data indicates a 7.2% CAGR (2023–2030) driven by diabetes prevalence. Product selection criteria prioritize stability, reconstitution time, and regulatory certifications (FDA, EMA). Logistics require cold chain (2–8°C) for lyophilized forms. The sector demands rigorous factory GMP audits and peptide purity >98% via HPLC.